Compare MGM Resorts International (MGM) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Sanofi SA — how do they compare? MGM Resorts International trades at $43.96 (market cap $11.10B), while Sanofi SA trades at $43.57 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 9.4× MGM Resorts International's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| MGM | SNY | |
|---|---|---|
Market Cap | $11.10B | $104.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $52.34 |
52-Week Low | $30.72 | $41.33 |
Enterprise Value | $38.40B | $124.19B |
Dividend Yield | 0.03% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International trades at $43.94, up 1.34% on the day, with a bearish technical signal from moving averages. The company reported record Q2 2026 revenue but missed earnings estimates, with net income margin at 2.4% for 2025. Recent news highlights a pending shareholder investigation into a proposed acquisition offer and expansion of BetMGM's partnerships in Canada.
The outlook is mixed: analyst consensus is a Buy with a $51.14 price target, indicating potential upside, but risks include margin pressure, high debt, and acquisition uncertainty. Earnings growth in Las Vegas and digital segments offers opportunity, yet competition and regulatory scrutiny pose challenges for shareholder value.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
